Perceptual learning promising therapy for progressive keratoconus patients intolerant to contact lenses: Study

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-09-22 16:45 GMT   |   Update On 2024-09-23 06:09 GMT

CAPTION

Rose-tinted contact lenses (about 10 mm in diameter) containing gold nanoparticles filter out problematic colors for people with red-green color blindness.

CREDIT

Adapted from ACS Nano 2021, DOI: 10.1021/acsnano.0c09657

Researchers have recently reported improvement of vision in patients with keratoconus (KC) even if spectacle correction was insufficient. Researchers have discovered that perceptual learning (PL) significantly improves the vision of patients with keratoconus, even when spectacle correction fails to correct vision. A recent randomized, double-blind clinical study has revealed that PL enhances the visual acuity not only of non-progressive patients with KC, but retains these improvements months after the end of treatment. The study was published in the American Journal of Ophthalmology by Xiang T. and colleagues.

This is a randomized, double-masked clinical study of 35 non-progressive KC patients, at least 9 years of age. All patients had unsatisfied spectacle-corrected visual acuity and were intolerant to contact lenses. Patients must have best spectacle-corrected distance visual acuity (CDVA) ranging from 0 to 1.0 logMAR (from Snellen visual acuity of 20/20 to 20/200).

Participants were divided into one of two groups: the PL group, who received perceptual learning training, and a control group who received placebo training for 3 months. Different visual outcomes such as CDVA, contrast sensitivity function (CSF), stereo acuity, and visual functioning and quality of life were measured on initiation of the trial (baseline) and at the end of 3 months post-training and at 6 months follow-up post-trial initiation.

Advertisement

Results

• The study demonstrated impressive improvement of vision for the patients who received perceptual learning.

• After 3 months of treatment, the PL group improved significantly more than the placebo group by -0.17 ± 0.15 logMAR compared to the placebo group which only improved by -0.02 ± 0.06 logMAR (P = 0.0006).

• In addition, this benefit was maintained at least for 6 months with the PL group having relatively better visual results than the placebo group (0.17 ± 0.17 logMAR vs. 0.01 ± 0.07 logMAR, P = 0.0011).

• Further, 47.06% (8 of 17) patients in the PL group achieved an improvement of at least 2 lines in CDVA (P = 0.0010).

• Contrast sensitivity function, also was enhanced in the PL group by a mean of 0.11 ± 0.17 log units at 3 cycles per degree and 0.12 ± 0.19 log units at 6 cycles per degree.

• In contrast, linear regression analysis revealed that subjects with poorer starting CDVA are more likely to achieve higher benefits following PL training (P = 0.009). No side effects were reported, and trainees completed the course with ease.

For those unsatisfied with spectacle-corrected visual acuity, three months of perceptual training strongly increased vision in keratoconus patients and endured at least 6 months after treatment ended. Results showed that perceptual learning may be a useful therapy to improve vision in keratoconus patients, particularly those who cannot wear contact lenses. It sheds an understanding of the potential of perceptual learning as an interesting, non-invasive treatment option in raising visual outcomes with patients bearing the keratoconus diagnosis.

Reference:

Tang, X.-H., Wang, M.-Y., Jiang, J.-Y., Zhou, F.-Q., Li, D., Chen, S.-S., Xiang, C.-Q., Lei, X.-Y., Hu, Y., & Yang, X. (2024). Vision improvement in keratoconus patients trained with perceptual learning: A randomized controlled trial. American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2024.08.032

Tags:    
Article Source : American Journal of Ophthalmology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News